KOSDAQ - Delayed Quote KRW

Choong Ang Vaccine Laboratory Co., Ltd. (072020.KQ)

10,700.00 0.00 (0.00%)
At close: 3:30 PM GMT+9
Loading Chart for 072020.KQ
DELL
  • Previous Close 10,700.00
  • Open 10,700.00
  • Bid 10,700.00 x --
  • Ask 10,710.00 x --
  • Day's Range 10,650.00 - 10,740.00
  • 52 Week Range 9,960.00 - 15,400.00
  • Volume 36,648
  • Avg. Volume 46,231
  • Market Cap (intraday) 103.348B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Aug 12, 2024 - Aug 16, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Choong Ang Vaccine Laboratory Co., Ltd., operates as an animal vaccine company, primarily engages in the production and sale of pharmaceutical products that promote animal health and welfare in Korea. Its vaccine products include SuiShot, PoulShot, CaniShot, BoviShot, FeliShot, RabbiShot, and AquaShot for preventing diseases and infection in pigs, poultry, dogs, cattle, cats, rabbits, and fish. The company was founded in 1968 and is based in Daejeon, South Korea.

www.cavac.co.kr

167

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 072020.KQ

Performance Overview: 072020.KQ

Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

072020.KQ
2.82%
KOSPI Composite Index
1.03%

1-Year Return

072020.KQ
7.55%
KOSPI Composite Index
3.12%

3-Year Return

072020.KQ
42.35%
KOSPI Composite Index
17.40%

5-Year Return

072020.KQ
49.55%
KOSPI Composite Index
29.73%

Compare To: 072020.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 072020.KQ

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.54%

  • Return on Assets (ttm)

    1.78%

  • Return on Equity (ttm)

    3.53%

  • Revenue (ttm)

    36.93B

  • Net Income Avi to Common (ttm)

    3.15B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.14B

  • Total Debt/Equity (mrq)

    11.60%

  • Levered Free Cash Flow (ttm)

    -12.07B

Research Analysis: 072020.KQ

Company Insights: 072020.KQ

Research Reports: 072020.KQ

People Also Watch